In 2014,Kedari, Chaitanya Kumar; Roy Choudhury, Nilanjana; Sharma, Sreevalli; Kaur, Parvinder; Guptha, Supreeth; Panda, Manoranjan; Mukerjee, Kakoli; Ramachandran, Vasanthi; Bandodkar, Balachandra; Ramachandran, Sreekanth; Tantry, Subramanyam J. published 《Biarylmethoxy Nicotinamides As Novel and Specific Inhibitors of Mycobacterium tuberculosis》.ACS Medicinal Chemistry Letters published the findings.Category: pyridine-derivatives The information in the text is summarized as follows:
A whole cell based screening effort on a focused library from corporate collection resulted in the identification of biarylmethoxy nicotinamides as novel inhibitors of M. tuberculosis (Mtu) H37Rv. The series exhibited tangible structure-activity relationships, and during hit to lead exploration, a cellular potency of 100 nM was achieved, which is an improvement of >200-fold from the starting point. The series is very specific to Mtu and noncytotoxic up to 250 μM as measured in the mammalian cell line THP-1 based cytotoxicity assay. This compound class retains its potency on several drug sensitive and single drug resistant clin. isolates, which indicate that the compounds could be acting through a novel mode of action. In the experimental materials used by the author, we found Methyl 5-bromopicolinate(cas: 29682-15-3Category: pyridine-derivatives)
Methyl 5-bromopicolinate(cas: 29682-15-3) belongs to pyridine. Pyridine’s structure is isoelectronic with that of benzene, but its properties are quite different. Pyridine is completely miscible with water, whereas benzene is only slightly soluble. Like all hydrocarbons, benzene is neutral (in the acid–base sense), but because of its nitrogen atom, pyridine is a weak base.Category: pyridine-derivatives